Holen Sie sich die Stockscreener-App
69.83
0.73%
-0.51
Handel nachbörslich:
69.83
Schlusskurs vom Vortag:
$70.34
Offen:
$70.5
24-Stunden-Volumen:
386.21K
Relative Volume:
0.58
Marktkapitalisierung:
$2.95B
Einnahmen:
$17.39M
Nettoeinkommen (Verlust:
$-135.89M
KGV:
-15.05
EPS:
-4.64
Netto-Cashflow:
$-123.00M
1W Leistung:
+2.06%
1M Leistung:
+41.47%
6M Leistung:
+43.33%
1J Leistung:
+91.42%
1-Tages-Spanne:
$69.02
$71.13
1-Wochen-Bereich:
$66.44
$71.15
52-Wochen-Spanne:
$35.84
$71.15
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Firmenname
Tarsus Pharmaceuticals Inc
Sektor
Branche
Telefon
(949) 409-9820
Adresse
15440 LAGUNA CANYON ROAD, IRVINE
Vergleichen Sie TARS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
69.83 | 2.97B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-20 | Eingeleitet | Goldman | Neutral |
| 2023-07-18 | Eingeleitet | William Blair | Outperform |
| 2023-05-18 | Eingeleitet | Guggenheim | Buy |
| 2022-08-01 | Eingeleitet | Barclays | Overweight |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-23 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-10 | Eingeleitet | BofA Securities | Buy |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-11-10 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Tarsus Pharmaceuticals (TARS) Is Up 15.1% After Xdemvy Demand and Pipeline Advances What's Changed - Sahm
Why Tarsus Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Retail & AI Enhanced Trade Execution Alerts - newser.com
How sentiment analysis helps forecast Tarsus Pharmaceuticals Inc.Dip Buying & Intraday High Probability Setup Alerts - newser.com
Can a trend reversal in Tarsus Pharmaceuticals Inc. lead to recoveryRecession Risk & Scalable Portfolio Growth Ideas - newser.com
Can Tarsus Pharmaceuticals Inc. rally from current levelsJuly 2025 Sentiment & Stock Portfolio Risk Management - newser.com
Can Tarsus Pharmaceuticals Inc. stock resist market sell offsWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Is Tarsus Pharmaceuticals Inc. building a consolidation base2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockMarket Activity Summary & Smart Allocation Stock Tips - newser.com
Will Tarsus Pharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Reactions & Capital Efficient Trading Techniques - newser.com
Tarsus Pharmaceuticals Hits New 52-Week High of $68.00 - Markets Mojo
Tarsus Pharmaceuticals Experiences Evaluation Revision Amid Strong Market Performance Indicators - Markets Mojo
Should you hold or exit Tarsus Pharmaceuticals Inc. nowWeekly Market Outlook & Accurate Intraday Trade Tips - newser.com
Will Tarsus Pharmaceuticals Inc. benefit from macro trendsWeekly Trade Recap & Daily Profit Maximizing Tips - newser.com
Tarsus Pharmaceuticals Achieves 101.95% Annual Growth, Solidifying Status as Multibagger Stock - Markets Mojo
Using data models to predict Tarsus Pharmaceuticals Inc. stock movementWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
Applying big data sentiment scoring on Tarsus Pharmaceuticals Inc.Breakout Watch & Safe Capital Investment Plans - newser.com
Trend analysis for Tarsus Pharmaceuticals Inc. this weekInsider Buying & Breakout Confirmation Trade Signals - newser.com
Tarsus Pharmaceuticals Hits New 52-Week High of $70.58 - Markets Mojo
Tarsus Pharmaceuticals (TARS): Evaluating Valuation After Xdemvy’s Strong Sales Growth and New Pipeline Announcements - Sahm
BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80 - MarketScreener
Weiss Ratings Reaffirms "Sell (D-)" Rating for Tarsus Pharmaceuticals (NASDAQ:TARS) - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 21.6% After Xdemvy’s Uptake and New Trial Announcements—And What's Next - Yahoo Finance
Tarsus Pharmaceuticals stock hits all-time high at 69.6 USD By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals stock hits all-time high at 69.6 USD - Investing.com
Tarsus Pharmaceuticals Hits New 52-Week High of $69.49 - Markets Mojo
Tarsus Pharmaceuticals Inc Stock Analysis and ForecastPrice Momentum Alerts & Investment Recommendations You Can Trust - earlytimes.in
Tarsus Pharmaceuticals Hits Day High with 10.89% Surge in Stock Price - Markets Mojo
Tarsus Pharmaceuticals Hits New 52-Week High of $65.97, Surges 101% - Markets Mojo
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week HighWhat's Next? - MarketBeat
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance
How Tarsus Pharmaceuticals Inc. stock reacts to inflationary pressures2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
How Tarsus Pharmaceuticals Inc. stock trades before earningsEarnings Recap Summary & Consistent Profit Trading Strategies - newser.com
Is Tarsus Pharmaceuticals Inc. forming a bottoming baseJuly 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 9.6% HigherTime to Buy? - MarketBeat
Tarsus Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
TARS Shares Roar Back: Explore The Surge - timothysykes.com
BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
Finanzdaten der Tarsus Pharmaceuticals Inc-Aktie (TARS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):